WuXi Biologics Receives Fourth Consecutive “Most Honored Company” and Other Top Awards in Institutional Investor Executive Team Rankings
SHANGHAI, Nov. 10, 2022—WuXi Biologics (“WuXi Bio”) (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that for the fourth consecutive year it has been recognized as a “Most Honored Company” in the 2022 Asia (ex-Japan) Executive Team rankings by Institutional Investor, an international financial publication. WuXi Biologics also took the top spot in five award categories in the Asia pharmaceutical sector: Best CEO, Best CFO, Best IR Professional, Best IR Program and Best ESG (Environmental, Social and Governance) Company.
As a leading international financial publisher, Institutional Investor creates its research-supported rankings and names award recipients based on combined buy- and sell-side surveys within the industry. This year, 4,854 investment professionals at 1,612 financial services firms cast votes and evaluated core areas, including the accessibility of senior executives, execution of strategy, a well-informed and empowered IR Team, timeliness of disclosure, and ESG performance.
Dr. Chris Chen, CEO of WuXi Biologics, commented, “We are greatly encouraged by the recognition from Institutional Investor, and the capital market that it represents. Despite the uncertainties brought by the global dynamic situation, WuXi Biologics’ strong execution will empower us to tackle challenges as they arise. We are confident of future growth, as we reaffirm growth and profit targets for 2022 and our commitment to enabling global partners for the benefit of patients worldwide.”
Looking ahead, WuXi Biologics will continue its growth momentum and maintain transparent communications with the market. The company is also committed to the ongoing implementation of its ESG strategy, the success of which has been demonstrated by multiple positive global ESG ratings, including Sustainalytics and FTSE4Good Index.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2022, WuXi Biologics is supporting 534 integrated client projects, including 14 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com